{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VYVANSE", "query": { "intervention": "VYVANSE" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 96, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VYVANSE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T00:07:11.325Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01435759", "title": "SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg", "type": "DRUG" }, { "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg", "type": "DRUG" }, { "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg", "type": "DRUG" }, { "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg", "type": "DRUG" }, { "name": "Antidepressant + Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1197, "start_date": "2011-05-31", "completion_date": "2014-01-17", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 60, "location_summary": "Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01435759" }, { "nct_id": "NCT01148979", "title": "Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Lisdexamfetamine Dimesylate (Vyvanse)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2010-09", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148979" }, { "nct_id": "NCT01552902", "title": "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention-deficit/Hyperactivity Disorder" ], "interventions": [ { "name": "Lisdexamfetamine dimesylate", "type": "DRUG" }, { "name": "Methylphenidate Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 549, "start_date": "2012-04-03", "completion_date": "2014-05-22", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 81, "location_summary": "Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Colton", "state": "California" }, { "city": "Imperial", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552902" }, { "nct_id": "NCT00247572", "title": "Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attention Deficit Disorder With Hyperactivity", "Amphetamine-Related Disorders", "Substance-Related Disorders" ], "interventions": [ { "name": "NRP104", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New River Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2005-09", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2007-11-05", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00247572" }, { "nct_id": "NCT01074294", "title": "Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "OPDC-34712", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Stimulant Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 740, "start_date": "2010-03-16", "completion_date": "2011-06-20", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074294" }, { "nct_id": "NCT01399827", "title": "Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attention Deficit Hyperactivity Disorder (ADHD)", "Deficient Emotional Self-Regulation (DESR)" ], "interventions": [ { "name": "ADHD Medication", "type": "DRUG" }, { "name": "Omega-3 Fatty Acids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2, "start_date": "2012-02", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399827" }, { "nct_id": "NCT00784654", "title": "Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Lisdexamfetamine dimesylate (LDX)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 276, "start_date": "2009-01-27", "completion_date": "2011-10-26", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 4, "location_summary": "Rolling Hills Estates, California • South Miami, Florida • Overland Park, Kansas + 1 more", "locations": [ { "city": "Rolling Hills Estates", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784654" }, { "nct_id": "NCT01718483", "title": "SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Binge Eating Disorder" ], "interventions": [ { "name": "SPD489 (Lisdexamfetamine dimesylate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 383, "start_date": "2012-11-26", "completion_date": "2013-09-25", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Corona, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01718483" }, { "nct_id": "NCT00985725", "title": "SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "SPD489 (Lisdexamfetamine dimesylate)", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 143, "start_date": "2009-10-29", "completion_date": "2011-04-18", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 33, "location_summary": "Imperial, California • Los Alamitos, California • Oceanside, California + 28 more", "locations": [ { "city": "Imperial", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Cromwell", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00985725" }, { "nct_id": "NCT00801229", "title": "Effect of Vyvanse on Driving in Young Adults With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention Deficit/Hyperactivity Disorder(ADHD)" ], "interventions": [ { "name": "Vyvanse", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "18 Years to 24 Years" }, "enrollment_count": 75, "start_date": "2008-12", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2014-03-10", "last_synced_at": "2026-09-09T00:07:11.325Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801229" } ] }